Genmab — Oktober 2017
-
med det nuværende omstningsniveau burde vi krydse blockbustergrænsen i november.
-
uden vækst ifht Q3 burde det ske 6,6 dage inde i november
-
enig
-
sjovt nok, så burde det være lige oveni GENs Q3 announcement
-
jeg sidder og kigger på GEN events i den nære fremtid og falder over den 14 december i Oslo. Gad vide om det har noget med oliefonden at gøre?
-
probably
-
129mill på en måned, er det ikke lettere optimistisk?
-
Nu var det en alt andet lige beregning. Combo i Europa og dara+pom i US må da for fanden snart få noget tracktion. Så oktober forhåbentlig
-
The alliances are focused on three key areas: infectious diseases including HIV, respiratory illnesses such respiratory syncytial virus (RSV), and infections acquired in health facilities like hospital-acquired flu. In addition to the research deals, Vir has also acquired Humabs BioMed, a Swiss company that’s developing more than 15 antibodies to treat diseases ranging from Zika to hepatitis B
-
Men vi har jo ikke rigtig set resultater af dara+pom label expansion i omsætningen endnu
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind